Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Journal: Nature
Published: August 05, 2026
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Journal: Nature
Published: February 16, 2026
Interchangeability Of Biological Drug Products-FDA Draft Guidance.
Journal: Journal of biopharmaceutical statistics
Published: April 27, 2019
A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
Journal: Advances in therapy
Published: December 21, 2018
A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
Journal: Cancer chemotherapy and pharmacology
Published: August 30, 2018
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
Journal: Cancer chemotherapy and pharmacology
Published: November 22, 2017
A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
Journal: Cancer chemotherapy and pharmacology
Published: June 21, 2017
Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 26, 2017
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects.
Journal: Cancer chemotherapy and pharmacology
Published: February 20, 2017
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab.
Journal: Annals of the rheumatic diseases
Published: November 17, 2015
The use of pharmacometrics to optimize biosimilar development.
Journal: Journal of pharmaceutical sciences
Published: September 19, 2012
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 07, 2011
Showing 1-12 of 12
Last Updated: 09/26/2026